IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
https://www.nature.com/articles/s41467-019-13731-z
Abstract
IL-17-producing CD8+ (Tc17) cells are enriched in active lesions of patients with multiple sclerosis (MS), suggesting a role in the pathogenesis of autoimmunity.
Here we show that amelioration of MS by dimethyl fumarate (DMF), a mechanistically elusive drug, associates with suppression of Tc17 cells. DMF treatment results in reduced frequency of Tc17, contrary to Th17 cells, and in a decreased ratio of the regulators RORC-to-TBX21, along with a shift towards cytotoxic T lymphocyte gene expression signature in CD8+ T cells from MS patients.
Mechanistically, DMF potentiates the PI3K-AKT-FOXO1-T-BET pathway, thereby limiting IL-17 and RORγt expression as well as STAT5-signaling in a glutathione-dependent manner. This results in chromatin remodeling at the Il17 locus. Consequently, T-BET-deficiency in mice or inhibition of PI3K-AKT, STAT5 or reactive oxygen species prevents DMF-mediated Tc17 suppression.
Overall, our data disclose a DMF-AKT-T-BET driven immune modulation and suggest putative therapy targets in MS and beyond.
Dimethyl fumarate associates with CD8+ cells reduction
-
- Similar Topics
- Replies
- Views
- Last post
-
- 4 Replies
- 1550 Views
-
Last post by DIM
-
- 2 Replies
- 1067 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1400 Views
-
Last post by Petr75
-
- 1 Replies
- 1122 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 1085 Views
-
Last post by frodo
-
- 0 Replies
- 948 Views
-
Last post by frodo
-
- 0 Replies
- 2278 Views
-
Last post by frodo
-
- 0 Replies
- 1904 Views
-
Last post by Firidion